Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 1998

View Archived Issues

Innovative Therapies for Rheumatoid Arthritis

Pivotal Zadaxin trial to begin in Japan

Connetics completes phase I/II MS trial; European patent granted

Targon and Duke University form oncology alliance

Timentin cleared for pediatric use in U.S.

Hydroxamic acid-based inhibitors of TNF and/or MMPs under study at Zeneca

Merck & Co.'s new HIV protease inhibitors

Pfizer presents new serotonergic agents

Inhibitors of COX-1/COX-2 from Roche

New cephems described by Fujisawa

Japan Energy describes inhibitors of SMC proliferation

New 5-HT1B antagonists developed at SmithKline Beecham

Yamasa presents novel xanthine oxidase inhibitors

Korean researchers characterize new antimicrobial/cytotoxic compound of microbial origin

Repligen and Glaxo extend Glyceptor collaboration

T Cell Sciences and Walter Reed collaborate on inhibition of liposome-induced complement activation

Dexketoprofen trometamol approved in E.U. countries

Botox compared to saline for chronic anal fissure

HMR and Abbott sign marketing agreement for Anzemet

Gastrimmune significantly increases survival in advanced colorectal cancer

Genetronics to begin phase II head and neck cancer trial in Canada

Commencement of Ossigel clinical trials

Connetics amends payment terms, sells Canadian rights to Ridaura

HMR and Allelix end collaboration for treatment of schizophrenia

Searle and Yamanouchi join forces in broad research alliance

Titan reports results from preclinical Parkinson's trial

Streptogramins in the treatment of drug-resistant infections

New HIV-based gene delivery system pioneered at Oxford BioMedica

FDA accepts RenaGel NDA for filing

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...